The cell morphology data generated by high-content imaging is a new type of omics data, which is highly compatible with the strengths of AI models (i.e., image analysis) and strongly correlates with downstream biological indicators for evaluating candidate drugs.
Through the AI model's learning from large-scale data, it can be used to predict the downstream biological mechanisms of candidate drugs, in vivo and in vitro pharmacodynamics/toxicity, and even the results of human trials.